Buy Inventurus Knowledge Solutions Ltd for the Target Rs. 1,902 by Motilal Oswal Financial Services Ltd
TruBridge acquisition strengthens US presence
Strategically accretive deal, though near-term dilution likely
* IKS announced the acquisition of TruBridge, a leading healthcare IT and RCM services provider in the US, with revenue of USD347m in CY25, almost equal to IKS’s revenue base. TruBridge has ~3,700 employees, implying revenue per employee of ~USD94k vs. ~USD26k for IKS, and operates at significantly lower margins than IKS, indicating a strong potential for margin expansion. TruBridge is a significant player in the rural hospital EHR market, serving more than 700 community and critical access hospitals. This deal is expected to diversify the business into a sticky SaaS EHR segment and will enable IKS to offer an integrated suite of EMR and care enablement platform solutions to both existing and new clients. TruBridge’s data and technology assets, including its HFMA peer-reviewed suite of RCM offerings and EHR solutions, will also strengthen IKS’s capabilities as a technology-led, data-driven healthcare services group.
*Transaction details: IKS will acquire 100% shareholding of TruBridge for an enterprise value of up to USD565m (subject to customary adjustments for net debts and selling expenses) to be paid in cash, representing USD26.25 per share. TruBridge will be a step-down wholly owned subsidiary of IKS. To fund the acquisition, IKS will raise a USD650m five-year term loan at initial interest rate of SOFR + 275bp, sliding down to 175bp as leverage reduces over time. Leverage is expected at 3x EBITDA of the combined entity. This transaction is expected to complete within 180 days or in 2QFY27.
* TruBridge reported revenue of USD347m in CY25 (USD342m in CY24), and has not provided any formal guidance for CY26; however, during 4QCY25 earnings call, management indicated expectations of modest revenue growth during the strategic review phase, along with ~200bp margin expansion in adjusted EBITDA.
* The combined entity is expected to deliver a pro forma EBITDA margin of ~23%, indicating margin dilution as TruBridge is operating at EBITDA margin of 12-13% compared to 33% for IKS.
* We note that the scale of the transaction is large; therefore, execution is critical. Integration, leadership retention, post-integration margin management, and amortization will be the key monitorables.
* We believe the TruBridge acquisition is strategically transformative and long-term value accretive for IKS. It will strengthen the company’s presence in the US healthcare ecosystem through its entry into sticky SaaS-based EHR and RCM platforms serving community and rural hospitals. It will also expand IKS’s distribution reach and create sizeable cross-sell opportunities across TruBridge’s entrenched hospital client base. We have not yet incorporated TruBridge’s numbers into valuation as it will be margin and profit dilutive due to a relatively low margin profile and a debt-funded structure. Consequently, we reiterate our BUY rating on the stock with a TP of INR1,902 (based on 30x FY28E EPS).
Rationale for acquisition
* Expands addressable market and client base: The acquisition will provide access to a large network of 700+ community and critical access hospitals in the US, which will significantly broaden IKS’s reach.
* Diversifies business mix into sticky SaaS revenue: It will add a recurring, highretention SaaS-based EHR business, which will improve revenue visibility and reduce dependence on pure services-led revenue streams.
* Creates integrated healthcare platform offering: The combination will enable IKS to offer an end-to-end suite spanning EHR, RCM, EMR, and care enablement solutions, enhancing cross-sell opportunities across existing and new clients.
* Strengthens technology and data capabilities: TruBridge’s technology platforms, proprietary healthcare data assets, and HFMA peer-reviewed RCM solutions reinforce the company’s positioning as a technology-led, data-driven healthcare solutions provider.
* Deepens presence in underserved hospital markets: The acquisition will strengthen exposure to community, rural, and critical access hospitals, a niche but underserved segment with long-term outsourcing and digitization potential.
* Enhances scale and financial profile: After acquisition, TruBridge will becomes wholly owned subsidiary, expanding consolidated revenue, asset base, and strategic footprint in the US healthcare IT market.
* We believe that overall, this acquisition will accelerate IKS’s evolution from a services-oriented player to a broader healthcare technology and platform-led enterprise. It will improve competitive positioning of IKS over the long term, though in the near term, margin dilution and debt will impact earnings.
Deal valuation and leverage
* The transaction values TruBridge at an implied multiple of ~1.6x EV/sales and 13x EV/EBITDA, based on CY25 financials. The valuation is slightly below the average valuation multiple paid in other transactions in the healthcare RCM space – R1RCM acquired by TowerBrook and CD&R at 14x EBITDA; New Mountain Capital invested in Access Healthcare at 16x EBITDA; and EQT acquired GeBBS Healthcare at 17x EBITDA. We believe this could be attributed to margin-related concerns.
* To fund the acquisition, IKS will raise a USD650m five-year term loan at an initial interest rate of SOFR + 275bp, sliding down to 175bp as leverage reduces over time. Leverage is expected at 3x EBITDA of the combined entity.
Acquisition integration and our take:
* As per management, the next 4-5 quarters after the acquisition will largely be an execution and transition phase, with near-term focus on integration, operational stabilization and laying foundation for revenue synergies. For that, management will focus on client retention, employee transition, technology stack integration, aligning operating structure, delivery models, and GTM initiatives. In the initial quarters, the combined entity will witness margin dilution due to the lowmargin profile of TruBridge. However, management said SG&A rationalization, operational efficiency measures, and public company cost elimination would be the first visible margin levers. In the long run, we believe more meaningful benefits to come from offshoring, automation and productivity gains.
View and Valuation
We believe the acquisition of TruBridge is strategically transformative and long-term value accretive for IKS. It will strengthen the company’s presence in the US healthcare ecosystem through its entry into sticky SaaS-based EHR and RCM platforms serving community and rural hospitals. It will also expand IKS’s distribution reach and create sizeable cross-selling opportunities across TruBridge’s entrenched hospital client base. We have not yet incorporated TruBridge’s numbers into valuation as it will be margin and profit dilutive due to the relatively low margin profile and a debt-funded structure. Consequently, we reiterate our BUY rating on the stock with a TP of INR1,902 (based on 30x FY28E EPS).
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
